According to Borui Pharmaceutical's announcement, the company has previously reviewed and passed a bill relating to the issuance of H shares and listing on the main board of the Hong Kong Stock Exchange. Since the previous declaration will expire soon, taking into account factors such as its own actual situation and changes in the domestic and foreign capital market environment, it was decided to terminate the listing and not continue to apply for an additional period of time. The termination was reviewed and approved by the 25th meeting of the fourth board of directors of the company. It falls within the scope of full authority authorized by the shareholders' meeting to handle the board of directors, and there is no need to submit it to the shareholders' meeting for consideration. The company's production and operation are currently stable and orderly, and this termination will not have a significant adverse impact on production, operation and sustainable development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.